Breaking News, Collaborations & Alliances

Aurinia Pharmaceuticals Acquires Kezar Life Sciences

Kezar’s lead product candidate is a first-in-class treatment for patients with autoimmune hepatitis, among other conditions.

Author Image

By: Patrick Lavery

Content Marketing Editor

Aurinia Pharmaceuticals has acquired Kezar Life Sciences, at a price of $6.955 per share of Kezar common stock. Aurinia develops therapies for patients with autoimmune diseases with unmet needs; Kezar’s focus is small-molecule therapeutics in autoimmunity and cancer. Kezar Lead Candidate Details Kezar’s lead product candidate, zetomipzomib, is a potentially first-in-class immunoproteasome inhibitor for patients with several conditions. These include autoimmune hepatitis (AIH), lupus nephri...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters